600 patients67,035 observations120 daysLIVE

Patient P-01844

Synthetic patientNBL-101 · Day 112 · 55–64 · M · baseline S04Steering view · 3DOpen companion preview
Is the drug working?

Therapy response 81 at the day-84 endpoint (observed).

Why responding?

Responding: response probability 80%, therapy response 79 today; biology is not blocking the drug.

Is a side effect starting?

No side effect starting: gi toxicity 8, systemic toxicity 14, no drift from the model.

Still taking it?

8 of 8 scheduled doses in the last 60 days are biologically confirmed (100%). Dose signature: resting HR +3 bpm, HRV −8 ms.

last 8 doses · green confirmed · amber logged only · red missed
Plan for this patient
stable, no actionrecommendowner · Companionreview day 119Human Model →
Next action
No action indicated; maintain.
Kept if

Trajectory is stable relative to similar patients; keep the current content.

Daily to-dos in the companion
  • 🍽Keep meals regular; three to four moderate portions spaced through the day
  • 🍽Include a cooked vegetable portion with each main meal
  • Log the daily check-in; one line is enough
  • A 15-minute walk after lunch
  • 💊Take the scheduled dose as agreed with your care team
  • 💊No additional supplements this week
Adherence
93% stable

Adherence is not the problem.

Changes the plan if

sleep quality falling under 35 while GI rises

LLIFE OS insight
grounded · add an LLM key for prose

P-01844 is on day 112 of NBL-101 (SR, baseline S04): response favorable, tolerance favorable, GI favorable. Over 14 days response moved -1 and GI -4; discontinuation risk is 6%. The state is in the restoration basin, heading towards restoration.

Biology sets the gain: Low microbial diversity; butyrate capacity 69/100, diversity 2.9. Pushing it down: Escherichia coli 20.459% (LPS load) (-35), 4 keystone species absent (-20.6), Alcohol (-17.8). Pulling it up: Butyrate producers intact (+11.7). From the daily log: alcohol +5.9 GI next day, simple carbs +3 GI next day.

No action has been tried yet.

No action is indicated now; the trajectory is stable relative to similar patients.

Therapy response
Favorable
Tolerance
Favorable
GI state
Favorable
Inflammatory state
Improving
Nutritional resilience
Favorable
Discontinuation risk
6%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted · dose (weekly infusion, day 1 of each 7-day cycle)
  1. Day 0 NBL-101 startedBaseline state S04

What changed?

Trajectory is tracking the baseline prediction.

Primary contributors, last 14 days
  • Inflammatory activity-8
  • GI instability-4
  • Toxicity-3
  • Nutritional resilience+2

What helped?

No interventions yet.

    LIFE OS recommendation
    No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

    Daily trackers

    Asset settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    GI burden
    Companion
    8.1/100
    improving · -13.5 vs previous 14 d
    Toxicity
    Blood
    13.6/100
    worsening · +5.3 vs previous 14 d
    Sleep quality
    Wearable
    57.1/100
    improving · +6.1 vs previous 14 d
    Energy level
    Daily log
    7.7/10
    improving · +0.6 vs previous 14 d
    Stress level
    Daily log
    3.2/10
    improving · -0.5 vs previous 14 d
    Steps
    Wearable
    4,767
    improving · +546 vs previous 14 d
    Adherence
    Companion
    92.5 %
    stable · +3.0 vs previous 14 d
    This trajectory is doing well — what to keep, what to watch
    Steering view →

    Heading towards restoration · 96 from the failing basin, 12 from restoration.

    Good elements to keep
    • Butyrate producers intact
      hidden · steering +11.7
    Main detractors to watch
    • Escherichia coli 20.459% (LPS load)
      hidden · steering -35
    • 4 keystone species absent
      hidden · steering -20.6
    • Alcohol
      perturbation · steering -17.8
    • Tissue recycling 45/100
      hidden · steering -13.2
    • Alcohol
      detractor · GI +5.9 next day
    • Simple carbohydrates
      detractor · GI +3 next day
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Alcohol
      +5.9detractor · 95%
    • Simple carbohydrates
      +3detractor · 79%
    • Spicy / capsaicin
      -2no signal · 38%
    • Insoluble fibre
      -0.9no signal · 17%
    • Dietary fat load
      +0.5no signal · 15%
    • Histamine load
      -0.1no signal · 15%

    DeepGene damage signature

    The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.

    Damage score · retest day 90
    73/100
    vs baseline (day 0)
    +16
    2 improved · 6 worsened
    synthetic signature · consistent with this patient's biology
    • 4 opportunists above range: Escherichia coli, Klebsiella pneumoniae, Enterococcus faecium
    • 4 keystone species absent
    • Shannon 2.37 (expected ≥ 3)
    • 7 resistance genes
    • Host DNA fragmentation atypical
    • Tissue recycling index 45
    Pathogens / opportunists4/5
    from 3
    Keystone species4/8
    from 3
    Diversity1/2
    Metabolic modules0/4
    Vitamin synthesis3/7
    Oral translocation1/1
    Host DNA1/1
    from 0
    Tissue recycling1/1
    Central mechanisms1/2
    Virulence factors4/4
    from 3
    Antibiotic resistance genes7/7
    Genetic predisposition2/2
    Opportunists above range
    Escherichia coli 20.459% AR
    Enterococcus faecium 10.229% AR
    Klebsiella pneumoniae 6.138% AR
    Clostridioides difficile 2.046% AR
    Keystone species absent
    Akkermansia muciniphila, Bifidobacterium longum, Butyricicoccus pullicaecorum, Eubacterium rectale
    Capacity
    Shannon 2.37 · butyrate 572 CPM · SCFA 951
    3 vitamins below
    Host & mechanisms
    host DNA fragmentation atypical
    tissue recycling 45/100
    oral translocation 4.65% AR
    estrobolome above
    7 resistance genes · 4 virulence factors

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Drug metabolism and exposure 35
      • DNADPYD *2A → slower clearance
    • Butyrate / short-chain fatty acid production 25
      • MicrobiomeF. prausnitzii depleted
    • Inflammatory signalling 20
      • MicrobiomeBacteroides fragilis expansion
    DNA
    Fictional pharmacogenomic panel
    • DPYD *2A heterozygous
      Slower drug clearance
    • CYP2D6 Normal metabolizer
      Expected exposure
    Microbiome
    Shannon diversity 2.9 · butyrate capacity 69/100
    • Akkermansia muciniphilaNormal
    • Faecalibacterium prausnitziiLow
    • Bacteroides fragilisHigh
    • Bifidobacterium longumNormal
    • EnterobacteriaceaeHigh
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    53 ms
    Sleep
    6.9 h
    Steps
    4,064
    Resting HR
    58 bpm
    Daily log: GI score 8, nutritional resilience 72, adherence 93.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Keep meals regular; three to four moderate portions spaced through the day
    • Include a cooked vegetable portion with each main meal
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Log the daily check-in; one line is enough
    • A 15-minute walk after lunch
    • Keep the sleep window steady
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • No additional supplements this week
    • Fictional demo item: continue vitamin D as before

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0148136%S15AD-05no change67
    P-0146827%S03AD-05no change50
    P-0176453%S15BR-03no change85
    P-0148948%S05BR-03improved83
    P-0141146%S13BR-03no change76
    P-0176644%S01BR-03improved83
    P-0189643%S06CR-01improved73
    P-0166440%S07CR-01improved85
    P-0142848%S18DT-01improved82
    P-0147246%S20DT-01no change82
    P-0152835%S20DT-01improved89
    P-0134230%S13DT-01improved59